Table 5.
Cumulative dosimetry estimates obtained in patients having completed three or four evaluable induction cycles (n = 65)
| Absorbed dose (Gy) | Relative error vs. 3TP (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3TP | 2TP | 1TPD3 | 2TP/1TPD1 | 2TP/1TPD3 | 2TP/NI | 2TP | 1TPD3 | 2TP/1TPD1 | 2TP/1TPD3 | 2TP/NI | |
| Kidney | 19.3 [11.8–23.6] (6.5–26.3) |
19.9 [11.8–24.3] (6.6–26.7) |
18.2 [10.7–24.4] (4.5–27.2) |
17.7 [11.1–24.5] (6.1–27.0) |
17.4 [10.6–23.5] (4.6–26.6) |
17.2 [9.9–25.3] (4.5–29.3) |
1.9 [0.1–3.8] (− 1.1–8.2) |
3.8 [− 24.2–6.3] (− 39.3–11.1) |
− 0.5 [− 26.1–9.6] (− 41.1–34.4) |
0.4 [−28.1–6.4] (− 40.4–33.2) |
− 7.1 [− 32.4–18.0] (− 42.8–38.3) |
| Bone marrowtotal | 1.10 [0.65–2.23] (0.52–9.59) |
1.07 [0.57–2.15] (0.48–9.68) |
0.89 [0.56–1.97] (0.38–6.9) |
0.80 [0.48–2.59] (0.32–7.37) |
0.86 [0.57–2.35] (0.38–8.05) |
0.86 [0.50–2.35] (0.40–9.51) |
−5.4 [− 9.5 to − 1.4] (− 19.0–3.9) |
13.3 [− 20.5 to − 4.1] (− 33.2 to − 0.7) |
− 15.7 [− 41.4–23.9] (− 61.2–68.8) |
−14.4 [− 24.7–9.0] (− 57.7–66.4) |
−20.3 [− 45.0–27.5] (− 72.9–110.3) |
| Tumormax | 129.0 [38.7–268.2] (15.3–473.2) |
131.9 [39.9–271.0] (15.8–466.2) |
107.6 [34.1–205.3] (16.8–390.6) |
118.8 [34.1–216.6] (15.4–402.9) |
118.9 [33.6–210.3] (13.0–416.1) |
155.4 [38.8–341.6] (14.0–575.2) |
1.4 [− 0.2–3.3] (− 1.5–4.3) |
−16.1 [− 45.9–3.2] (− 60.0–12.0) |
−5.6 [− 41.0–10.3] (− 62.7–39.5) |
−2.9 [− 40.2–6.4] (− 63.4–21.9) |
15.9 [− 29.2–80.5] (− 75.6–400.5) |
D1 day 1, D3 day 3, NI no imaging, TP time point(s)
Data is presented as median [interdecile range] (range)
Median cumulative injected activity was 30.5 (11.9–78.6) GBq